JeNaCell Receives Seed Financing from High-Tech Gründerfonds and STIFT
High-Tech Gründerfonds and STIFT are jointly investing €700,000 in JeNaCell GmbH
The business idea of JeNaCell GmbH, a spin-off of the Friedrich Schiller University in Jena, Germany, is based on a new and patented process for the continuous production of a high-performance biomaterial with natural nanostructures, which can be used for making innovative medical and cosmetic products. Due to its material qualities, it is not only extremely suitable for treating poorly healing wounds, but also makes possible highly promising applications for wellness products and in technology.
Dr. Heßler, Dr. Kralisch, and their team have succeeded in developing an efficient production process through which the fascinating biomaterial can be offered on the market in large quantities, at high quality, and economically. The seed capital is to be used for optimizing the products as well as building up an automated production facility. In addition, the financing will fund preparatory measures for the market introduction of the high-tech biomaterial.
“We are very happy that we have received the financial support from High-Tech Gründerfonds and STIFT that we need to grow from developmental work to an industrial scale,” says Dr. Nadine Hessler, CEO of JeNaCell GmbH.
Other news from the department science
